{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:30:48Z","timestamp":1767861048758,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.revmed.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T15:52:53Z","timestamp":1622044373000},"page":"575-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-Ma2 antibody encephalitis associated with Sjogren's syndrome"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7823-1827","authenticated-orcid":false,"given":"K.","family":"Chevalier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Noel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Benoudiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hacein-Bey-Abina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2021.05.006_bib0125","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10072-011-0510-y","article-title":"Anti-Ma2\/Ta antibodies in a woman with primary lateral sclerosis-like phenotype and Sj\u00f6gren syndrome","volume":"32","author":"Piccolo","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1016\/j.revmed.2021.05.006_bib0130","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/rheumatology\/kep210","article-title":"Lateral medullary syndrome with anti-neuronal antibodies (anti-Ta\/Ma2) in primary Sjogren's Syndrome","volume":"48","author":"Mehta","year":"2009","journal-title":"Rheumatol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0135","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00415-007-0596-6","article-title":"Asymmetric cerebellar ataxia and limbic encephalitis as a presenting feature of primary Sj\u00f6gren's syndrome","volume":"254","author":"Collison","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-510X(02)00034-5","article-title":"Motor weakness and cerebellar ataxia in Sj\u00f6gren syndrome\u2013identification of antineuronal antibody: a case report","volume":"197","author":"Owada","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.revmed.2021.05.006_bib0145","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0140-6736(94)91864-3","article-title":"Antineuronal antibody in Sj\u00f6gren's syndrome masquerading as paraneoplastic cerebellar degeneration","volume":"343","author":"Terao","year":"1994","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.revmed.2021.05.006_bib0150","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/brain\/awh203","article-title":"Clinical analysis of anti-Ma2-associated encephalitis","volume":"127","author":"Dalmau","year":"2004","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0155","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2021.05.006_bib0160","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.1288","article-title":"Molecular and clinical diversity in paraneoplastic immunity to Ma proteins","volume":"50","author":"Rosenfeld","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nrl.2016.05.010","article-title":"S\u00edndromes neurol\u00f3gicos paraneopl\u00e1sicos asociados a anticuerpos anti-Ma y anti-Ma2","volume":"33","author":"Ortega Suero","year":"2018","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.revmed.2021.05.006_bib0170","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJM199906103402303","article-title":"A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer","volume":"340","author":"Voltz","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2021.05.006_bib0175","doi-asserted-by":"crossref","first-page":"e8228","DOI":"10.1097\/MD.0000000000008228","article-title":"Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: a case report","volume":"96","author":"Ju","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2021.05.006_bib0180","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00415-018-9143-x","article-title":"Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome","volume":"266","author":"Vogrig","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1590\/0004-282x20160169","article-title":"Progressive hearing loss and cerebellar ataxia in anti-Ma2-associated autoimmune encephalitis","volume":"75","author":"Souza","year":"2017","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.revmed.2021.05.006_bib0190","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1212\/NXI.0000000000000557","article-title":"Atypical presentation of anti-Ma2-associated encephalitis with choreiform movement","volume":"6","author":"Lamby","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.revmed.2021.05.006_bib0195","doi-asserted-by":"crossref","DOI":"10.1136\/practneurol-2019-002464","article-title":"Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy","author":"Lyons","year":"2020","journal-title":"Pract Neurol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0200","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.2004.040378","article-title":"Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage","volume":"75","author":"Rees","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2021.05.006_bib0205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp.2007.118588","article-title":"Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases","volume":"79","author":"Hoffmann","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2021.05.006_bib0210","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.revmed.2021.05.006_bib0215","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.revmed.2021.05.006_bib0220","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11940-009-0007-7","article-title":"Treatment of anti-Ma2\/Ta paraneoplastic syndrome","volume":"11","author":"Kraker","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0225","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1111\/j.1468-1331.2012.03881.x","article-title":"Opsoclonus, limbic encephalitis, anti-Ma2 antibodies and gastric adenocarcinoma","volume":"19","author":"Biotti","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-005-9052-6","article-title":"Second primary tumor in anti-Ma1\/2-positive paraneoplastic limbic encephalitis","volume":"78","author":"Leyhe","year":"2006","journal-title":"J Neurooncol"},{"key":"10.1016\/j.revmed.2021.05.006_bib0235","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.revmed.2021.05.006_bib0240","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's Syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866321004550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866321004550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:44:13Z","timestamp":1759337053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866321004550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0248866321004550"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2021.05.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Ma2 antibody encephalitis associated with Sjogren's syndrome","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}